Literature DB >> 12237476

Prevalence of tetanus immunity in the Egyptian population.

El-Rashdy M Redwan1, Mostafa K Al-Awady.   

Abstract

Our aim was to determine the level of tetanus immunity in the general Egyptian population. The surveyed population consisted of 709 healthy subjects from five regions of Egypt, 2 month to 105 years of age. We used an ELISA assay to determine titers of anti-tetanus IgG. According to the widely used criteria, 31.7% was susceptible to tetanus (IgG level < 0.15 IU/ml), 15.7% protection (0.15-1.0 IU/ml), and 52.6% > or = 1.0 IU/ml). The results revealed that the majority (68.3%) population from 2 months to 50 years had a protective level of IgG against tetanus. The level of susceptibility increases with age until it reaches 90.3% Significantly, more males (23.7%) unprotected against tetanus. Our results suggest that monitoring immunization status and administering the tetanus vaccine as required are essential to insure adequate and long-lasting antibody levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237476

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  8 in total

1.  Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups.

Authors:  K Caglar; R Karakus; C Aybay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

2.  The seroepidemiology of tetanus in Catalonia, Spain.

Authors:  A Domínguez; P Plans; J Costa; J Espuñes; N Cardeñosa; L Salleras; A Plasència
Journal:  Med Microbiol Immunol       Date:  2007-01-23       Impact factor: 3.402

3.  Serological Monitoring Is Key To Sustain Progress of the Maternal and Neonatal Tetanus Elimination Initiative.

Authors:  Myron M Levine; Marcela F Pasetti
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

4.  Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma.

Authors:  Esmail M El-Fakharany; Nawal Abedelbaky; Bakry M Haroun; Lourdes Sánchez; Nezar A Redwan; Elrashdy M Redwan
Journal:  Virol J       Date:  2012-09-16       Impact factor: 4.099

5.  Prevalence and socio-demographic factors associated with non-protective immunity against tetanus among high school adolescents girls in Nigeria.

Authors:  Adebola E Orimadegun; Akinlolu A Adepoju; Olusegun O Akinyinka
Journal:  Ital J Pediatr       Date:  2014-03-17       Impact factor: 2.638

6.  Elevated Concentration of Defensins in Hepatitis C Virus-Infected Patients.

Authors:  Ehab H Mattar; Hussein A Almehdar; Abdullah A AlJaddawi; Isam ElDin M Abu Zeid; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-06-20       Impact factor: 4.818

7.  Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.

Authors:  Ghassan Dbaibo; Nabil El-Ayoubi; Soha Ghanem; Farah Hajar; Veronique Bianco; Jacqueline M Miller; Narcisa Mesaros
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

8.  Immunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia.

Authors:  Mark A Travassos; Berhane Beyene; Zenaw Adam; James D Campbell; Nigisti Mulholland; Seydou S Diarra; Tassew Kassa; Lisa Oot; Jenny Sequeira; Mardi Reymann; William C Blackwelder; Yukun Wu; Inna Ruslanova; Jaya Goswami; Samba O Sow; Marcela F Pasetti; Robert Steinglass; Amha Kebede; Myron M Levine
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.